Mouse Monoclonal acetyl Lysine antibody. Suitable for ChIP, WB, ICC/IF and reacts with Modified Amino Acid samples. Cited in 19 publications.
Preservative: 0.05% Sodium azide
Constituents: PBS, 0.1% BSA
ChIP | WB | ICC/IF | |
---|---|---|---|
Modified Amino Acid | Tested | Tested | Tested |
Species | Dilution info | Notes |
---|---|---|
Species Modified Amino Acid | Dilution info 10 µg/mL | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Modified Amino Acid | Dilution info 1/500.00000 - 1/2000.00000 | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Modified Amino Acid | Dilution info 1/100.00000 - 1/500.00000 | Notes - |
Select an associated product type
pan acetyl Lysine
Mouse Monoclonal acetyl Lysine antibody. Suitable for ChIP, WB, ICC/IF and reacts with Modified Amino Acid samples. Cited in 19 publications.
Preservative: 0.05% Sodium azide
Constituents: PBS, 0.1% BSA
ab22550 recognises proteins with acetylated lysine.
Acetyl lysine often referred to as acetylated lysine is a modification of the amino acid lysine where an acetyl group is transferred to the lysine residue. This modification impacts the mass of the lysine residue slightly altering its properties. Acetyl lysine occurs in histone proteins and this modification is an important regulator of chromatin structure and function. The acetylation of lysine residues happens frequently in the nucleus of eukaryotic cells where histone acetylases (HATs) facilitate this process. Known alternatively as lysine acetylation it represents an important post-translational modification impacting gene expression regulation.
Acetylation adds an acetyl group to the lysine which changes its positive charge reducing chromatin compaction and enhancing gene transcription. The acetyl lysine modification is not acting alone; it forms part of larger histone modification complexes. By altering chromatin structure acetyl lysine regulates the accessibility of transcription factors to DNA influencing various biological processes like DNA repair replication and cell cycle progression. The interaction between acetyl lysine and chromatin remodeling complexes plays a significant role in epigenetic regulation.
Acetyl lysine is central to epigenetic regulatory pathways significantly impacting gene expression and cellular growth pathways. The acetylation process involves histone acetylases (HATs) such as the p300/CBP complex which adds acetyl groups to specific lysines on histones increasing transcriptional activity. Conversely histone deacetylases (HDACs) remove acetyl groups decreasing transcription. The balance of these modifications involves critical pathways such as the TGF-beta signaling pathway and the NF-kB pathway linking acetyl lysine with numerous cellular activities and protein interactions.
Dysregulation of acetyl lysine levels is associated with cancer and neurodegenerative diseases. In cancer the aberrant acetylation of lysine impacts expression of oncogenes and tumor suppressor genes contributing to carcinogenesis. Proteins like p53 which relies on acetylation for activation become functionally impaired. Also in neurodegenerative disorders such as Alzheimer's disease histone acetylation imbalances disrupt neuronal function and gene expression. The involvement of the sirtuin family of proteins which act as NAD+-dependent deacetylases connects lysine acetylation to these diseases highlighting its importance in maintaining normal cellular functions and its role in pathological states.
We have tested this species and application combination and it works. It is covered by our product promise.
We have not tested this specific species and application combination in-house, but expect it will work. It is covered by our product promise.
This species and application combination has not been tested, but we predict it will work based on strong homology. However, this combination is not covered by our product promise.
We do not recommend this combination. It is not covered by our product promise.
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
Chromatin Co-Immunoprecipitation (ChIP) analysis using ab22550 binding acetylated lysines in 10E+06 LNCaP cells. Protein binding was detected using real-time PCR.
Positive control: Fold enrichment of ab22550.
Negative Control: Non-specific IgG.
Immunoflouroescence analysis of HeLa Cells labelling lysine acetylated proteins with ab22550. Formalin fixed cells were permeabalized with 0.1& Triton X-100 in TBS for 10 mins at room temperature and subsequently blocked with BSA at room temperature for 15 mins. Cells were then probed with ab22550 at 1/100 for 1 hour at room temperature. The secondary used was a DyLight® 488 goat anti-mouse used at 1/400 for 30 minutes at room temperature. Additional counterstains used were F-actin with a DyLight® 554 Phalloidin and Neuclei stained using a Hoechst 33342 conjugate. Image was taken at X20 magnification.
Western blot analysis of lysine acetylated proteins from cells left untreated (DMSO only) or cells treated with 0.3uM or 3uM of Trichostatin A (TSA) for 16 hours was performed by loading 50 μg of the indicated whole cell lysates per well and 10 μL of PageRuler Prestained Protein Ladder onto a 4-20% Tris-HCl polyacrylamide gel. Proteins were transferred to a PVDF membrane and blocked with 5% BSA/TBST for at least 1 hour. The membrane was probed with an Acetyl Lysine monoclonal antibody at a dilution of 1:1000 overnight at 4°C on a rocking platform, washed in TBS-0.1%Tween-20, and probed with a goat anti-mouse IgG-HRP secondary antibody at a dilution of 1:20,000 for 1 hour. Chemiluminescent detection was performed using SuperSignal West Pico.
All lanes: Western blot - Anti-acetyl Lysine antibody [1C6] (ab22550) at 1/1000 dilution
Lane 1: HeLa (untreated) cell lysate at 50 µg
Lane 2: HeLa (treated with 0.3 uM TSA, 16h) cell lysate at 50 µg
Lane 3: HeLa (treated with 3 uM TSA, 16h) cell lysate at 50 µg
Lane 4: COS7 (untreated) cell lysate at 50 µg
Lane 5: COS7 (treated with 0.3 uM TSA, 16h) cell lysate at 50 µg
Lane 6: COS7 (treated with 3 uM TSA, 16h) cell lysate at 50 µg
Lane 7: C2C12 (untreated) cell lysate at 50 µg
Lane 8: C2C12 (treated with 0.3 uM TSA, 16h) cell lysate at 50 µg
Lane 9: C2C12 (treated with 3 uM TSA, 16h) cell lysate at 50 µg
ICC/IF image of ab22550 stained MCF7 cells. The cells were 4% formaldehye fixed (10 min) and then incubated in 1%BSA / 10% normal goat serum / 0.3M glycine in 0.1% PBS-Tween for 1h to permeabilise the cells and block non-specific protein-protein interactions. The cells were then incubated with the antibody (ab22550, 5µg/ml) overnight at +4°C. The secondary antibody (green) was Goat Anti-Mouse IgG H&L (DyLight® 488) preadsorbed ab96879, DyLight® 488 goat anti-mouse IgG (H+L) used at a 1/250 dilution for 1h. Alexa Fluor® 594 WGA was used to label plasma membranes (red) at a 1/200 dilution for 1h. DAPI was used to stain the cell nuclei (blue) at a concentration of 1.43µM.
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com